20
Oct
2022

Bezos Bets on Fred Hutch, Prime Medicine Bucks the Trend, and PacBio Throws Down

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Alzheimer’s Debate, Nimbus to Challenge BMS, & a Microbiome First
Vaxcyte Takes on Pfizer, Novartis Challenges AZ, & Time Gets $100M
Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore
Eisai and Biogen Bounce Back, Amylyx Approved, & Illumina’s Big Reveal